September 07, 2010
FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections
April 20, 2010
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2010
Earnings Per Share of $0.07, Including a One-Time Charge Totaling $0.76
Per Share
January 19, 2010
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share
December 23, 2009
Forest Laboratories Announces Acquisition of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor
October 20, 2009
Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Charge for One-Time Items
September 12, 2009
Forest Laboratories Presents Analysis of Two Positive Pivotal Phase III Studies of Ceftaroline for the Treatment of Community-Acquired Pneumonia (CAP) at ICAAC
August 12, 2009
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
June 19, 2009
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
April 21, 2009
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
